Genocea Biosciences Inc (GNCAQ)

[excboe]

Data due out by end of 3rd qrtr. That is 10 trading days from now. This is what Jonathan Poole said when Adam F. bashed the stock based on the fact that placebo was only for one month.


Thanks for the email. We have been clear that our ongoing Phase 2b trial will retain a placebo arm for the full 12 months. In Q3 we will report viral shedding rate reductions vs. placebo and baseline for the immediate post dosing observation period and around the end of the year we will be reporting our clinical efficacy data versus placebo at 6 months post dosing.

As you know the placebo arm in the dose optimization trial was included for comparative acute tolerability purposes only and it certainly is not new news that our 6 and 12 month data would not have a placebo comparator - this was entirely consistent with the primary endpoint of the trial, which was a change from baseline analysis in viral shedding - a standard way of measuring viral activity in genital herpes. The feedback which we receive from our investigators and experts in the field is that the weight of efficacy data which we have presented to date is compelling and they, and we, remain enthused about GEN-003's potential.

Jonathan Poole